Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies

Published:October 14, 2015DOI:


      To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current treatment strategies. Older agents such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab, and panitumumab, do not appear to be cost-effective treatments at their current costs. The analytical methods used within the papers varied widely, and this variation likely plays a significant role in the heterogeneity in incremental cost-effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective, and this is primarily driven by high drug costs.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.
        • Desantis C.
        • Jemal A.
        Colorectal cancer statistics, 2014.
        CA Cancer J Clin. 2014; 64: 104-117
        • Mariotto A.B.
        • Yabroff K.R.
        • Shao Y.
        • et al.
        Projections of the cost of cancer care in the United States: 2010-2020.
        J Natl Cancer Inst. 2011; 103: 117-128
        • Saltz L.B.
        • Clarke S.
        • Diaz-Rubio E.
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Seymour M.T.
        • Brown S.R.
        • Middleton G.
        • et al.
        Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
        Lancet Oncol. 2013; 14: 749-759
        • Grothey A.
        • Van Cutsem E.
        • Sobrero A.
        • et al.
        Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
        Lancet. 2013; 381: 303-312
        • Innocenti F.
        • Undevia S.D.
        • Iyer L.
        • et al.
        Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
        J Clin Oncol. 2004; 22: 1382-1388
        • Gamelin E.
        • Delva R.
        • Jacob J.
        • et al.
        Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
        J Clin Oncol. 2008; 26: 2099-2105
        • Wicherts D.A.
        • Miller R.
        • de Haas R.J.
        • et al.
        Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases.
        Ann Surg. 2008; 248: 994-1005
        • Bilchik A.J.
        • Faries M.
        Radiofrequency ablation of hepatic malignancies: inexpensive and minimally invasive but should it replace resection?.
        Ann Surg Oncol. 2003; 10: 1002-1004
        • Tumeh J.W.
        • Moore S.G.
        • Shapiro R.
        • et al.
        Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.
        Expert Rev Pharmacoecon Outcomes Res. 2005; 5: 153-162
        • Howard D.H.
        • Kauh J.
        • Lipscomb J.
        The value of new chemotherapeutic agents for metastatic colorectal cancer.
        Arch Intern Med. 2010; 170: 537-542
        • Tumeh J.W.
        • Shenoy P.J.
        • Moore S.G.
        • et al.
        A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
        Am J Clin Oncol. 2009; 32: 49-55
        • Hillner B.E.
        • Schrag D.
        • Sargent D.J.
        • et al.
        Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
        Cancer. 2005; 104: 1871-1884
        • Wong Y.N.
        • Meropol N.J.
        • Speier W.
        • et al.
        Cost implications of new treatments for advanced colorectal cancer.
        Cancer. 2009; 115: 2081-2091
        • Goldstein D.A.
        • Chen Q.
        • Ayer T.
        • et al.
        First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States–based cost-effectiveness analysis.
        J Clin Oncol. 2015; 33: 1112-1118
        • Shankaran V.
        • Mummy D.
        • Koepl L.
        • et al.
        Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.
        Oncologist. 2014; 19: 892-899
        • Behl A.S.
        • Goddard K.A.
        • Flottemesch T.J.
        • et al.
        Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
        J Natl Cancer Inst. 2012; 104: 1785-1795
        • Vijayaraghavan A.
        • Efrusy M.B.
        • Goke B.
        • et al.
        Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
        Int J Cancer. 2012; 131: 438-445
        • Goldstein D.A.
        • Chen Q.
        • Ayer T.
        • et al.
        Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
        Clin Colorectal Cancer. 2014; 13: 219-225
        • Gold H.T.
        • Hall M.J.
        • Blinder V.
        • et al.
        Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
        Cancer. 2009; 115: 3858-3867
        • Abbott D.E.
        • Sohn V.Y.
        • Hanseman D.
        • et al.
        Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases.
        J Surg Oncol. 2014; 109: 516-520
        • Karuna S.T.
        • Thirlby R.
        • Biehl T.
        • et al.
        Cost-effectiveness of laparoscopy versus laparotomy for initial surgical evaluation and treatment of potentially resectable hepatic colorectal metastases: a decision analysis.
        J Surg Oncol. 2008; 97: 396-403
        • Bang H.J.
        • Littrup P.J.
        • Currier B.P.
        • et al.
        Percutaneous cryoablation of metastatic lesions from colorectal cancer: efficacy and feasibility with survival and cost-effectiveness observations.
        ISRN Minim Invasive Surg. 2012; 2012
      1. Goldstein DA, Ahmad BB, Chen Q, et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol. 2015, pii: JCO.2015.61.9569. [Epub ahead of print].

        • Goldberg R.M.
        • Sargent D.J.
        • Morton R.F.
        • et al.
        Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
        J Clin Oncol. 2006; 24: 3347-3353
        • Colucci G.
        • Gebbia V.
        • Paoletti G.
        • et al.
        Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
        J Clin Oncol. 2005; 23: 4866-4875
        • De Roock W.
        • Claes B.
        • Bernasconi D.
        • et al.
        Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
        Lancet Oncol. 2010; 11: 753-762
        • Capitain O.
        • Asevoaia A.
        • Boisdron-Celle M.
        • et al.
        Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
        Clin Colorectal Cancer. 2012; 11: 263-267
        • Selzner M.
        • Hany T.F.
        • Wildbrett P.
        • et al.
        Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?.
        Ann Surg. 2004; 240: 1027-1034
        • Yabroff K.R.
        • Borowski L.
        • Lipscomb J.
        Economic studies in colorectal cancer: challenges in measuring and comparing costs.
        J Natl Cancer Inst Monogr. 2013; 2013: 62-78
        • Winkelmayer W.C.
        • Weinstein M.C.
        • Mittleman M.A.
        • et al.
        Health economic evaluations: the special case of end-stage renal disease treatment.
        Med Decis Making. 2002; 22: 417-430
        • Lee C.P.
        • Chertow G.M.
        • Zenios S.A.
        An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard.
        Value Health. 2009; 12: 80-87
        • Daigle M.E.
        • Weinstein A.M.
        • Katz J.N.
        • et al.
        The cost-effectiveness of total joint arthroplasty: a systematic review of published literature.
        Best Pract Res Clin Rheumatol. 2012; 26: 649-658
        • Lansingh V.C.
        • Carter M.J.
        • Martens M.
        Global cost-effectiveness of cataract surgery.
        Ophthalmology. 2007; 114: 1670-1678
        • Wiseman V.
        • Hawley W.A.
        • ter Kuile F.O.
        • et al.
        The cost-effectiveness of permethrin-treated bed nets in an area of intense malaria transmission in western Kenya.
        Am J Trop Med Hyg. 2003; 68: 161-167
        • Ellis L.M.
        • Bernstein D.S.
        • Voest E.E.
        • et al.
        American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
        J Clin Oncol. 2014; 32: 1277-1280
        • Saltz L.B.
        Can money really be no object when cancer care is the subject?.
        J Clin Oncol. 2015; 33: 1093-1094